Latest Ratios: P/E Ratio -0.0x · EV/EBITDA 9.9x · ROE -2111.6%. (1996–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $16M | $215M | $1.0B | $1.5B | $1.5B | $3.3B | $1.7B | $313M | $380M | $1.1B | $2.2B |
| Enterprise Value | $2.0B | $2.2B | $3.1B | $3.6B | $4.2B | $4.4B | $2.7B | $2.0B | $2.0B | $1.9B | $2.5B |
| P/E Ratio → | -0.01 | — | — | — | 67.34 | 14.80 | 57.55 | — | — | 15.73 | 20.05 |
| P/S Ratio | 0.01 | 0.08 | 0.09 | 0.14 | 0.15 | 0.34 | 0.20 | 0.03 | 0.04 | 0.12 | 0.22 |
| P/B Ratio | — | — | 1.77 | 1.58 | 1.57 | 3.50 | 2.41 | 0.68 | 0.73 | 1.12 | 2.25 |
| P/FCF | 0.13 | — | — | 2.74 | 9.40 | 44.08 | 6.14 | 2.75 | 7.61 | 187.65 | 13.75 |
| P/OCF | — | — | 6.21 | 1.97 | 4.58 | 26.44 | 5.06 | 1.89 | 3.29 | 19.95 | 11.53 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 0.78 | 0.29 | 0.35 | 0.42 | 0.45 | 0.32 | 0.21 | 0.21 | 0.21 | 0.26 |
| EV / EBITDA | 9.93 | 4.97 | 54.27 | 9.24 | 11.34 | 9.54 | 9.21 | 10.30 | — | 12.97 | 9.94 |
| EV / EBIT | 8.87 | 414.36 | — | 35.11 | 30.13 | 13.49 | 11.40 | 19.69 | — | 12.86 | 11.30 |
| EV / FCF | — | — | — | 6.80 | 26.59 | 58.82 | 9.79 | 17.17 | 39.36 | 319.54 | 16.17 |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 46.7% | 46.7% | 20.7% | 20.6% | 18.3% | 15.5% | 15.1% | 12.3% | 11.4% | 12.6% | 12.2% |
| Operating Margin | 8.0% | 8.0% | -1.9% | 1.0% | 1.4% | 3.8% | 2.4% | 0.8% | -3.7% | 1.0% | 2.1% |
| Net Profit Margin | -39.8% | -39.8% | -3.4% | -0.4% | 0.2% | 2.3% | 0.4% | -0.7% | -4.6% | 0.8% | 1.1% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -2111.6% | -2111.6% | -48.7% | -4.4% | 2.4% | 26.9% | 5.1% | -12.7% | -57.0% | 7.4% | 11.3% |
| ROA | -31.0% | -31.0% | -7.4% | -0.8% | 0.5% | 6.4% | 0.9% | -1.7% | -12.2% | 2.4% | 4.0% |
| ROIC | 8.0% | 8.0% | -5.4% | 2.3% | 3.8% | 14.7% | 8.0% | 2.6% | -13.5% | 4.2% | 11.2% |
| ROCE | 10.3% | 10.3% | -6.9% | 3.0% | 4.8% | 17.6% | 9.7% | 3.2% | -16.1% | 4.8% | 11.9% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | 3.79 | 2.60 | 2.95 | 1.23 | 1.60 | 3.70 | 3.18 | 0.89 | 0.59 |
| Debt / EBITDA | 5.12 | 5.12 | 37.54 | 6.14 | 7.52 | 2.51 | 3.83 | 9.00 | — | 6.06 | 2.21 |
| Net Debt / Equity | — | — | 3.70 | 2.34 | 2.88 | 1.17 | 1.44 | 3.55 | 3.06 | 0.78 | 0.39 |
| Net Debt / EBITDA | 4.47 | 4.47 | 36.67 | 5.52 | 7.33 | 2.39 | 3.44 | 8.65 | — | 5.35 | 1.49 |
| Debt / FCF | — | — | — | 4.06 | 17.19 | 14.74 | 3.65 | 14.42 | 31.75 | 131.89 | 2.42 |
| Interest Coverage | 0.05 | 0.05 | -1.49 | 0.65 | 1.08 | 6.75 | 2.88 | 1.01 | -5.02 | 4.72 | 8.29 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.58 | 0.58 | 1.08 | 1.11 | 1.47 | 1.73 | 1.59 | 1.70 | 1.72 | 1.67 | 1.90 |
| Quick Ratio | 0.50 | 0.50 | 0.47 | 0.52 | 0.61 | 0.61 | 0.67 | 0.89 | 0.85 | 0.91 | 1.01 |
| Cash Ratio | 0.30 | 0.30 | 0.03 | 0.13 | 0.04 | 0.04 | 0.09 | 0.05 | 0.05 | 0.08 | 0.18 |
| Asset Turnover | — | 1.13 | 2.30 | 2.03 | 1.85 | 2.77 | 2.54 | 2.53 | 2.50 | 2.76 | 3.58 |
| Inventory Turnover | 19.79 | 19.79 | 7.49 | 7.39 | 6.10 | 5.53 | 5.84 | 7.05 | 6.47 | 8.23 | 9.32 |
| Days Sales Outstanding | — | 12.67 | 23.54 | 21.13 | 27.99 | 25.42 | 30.16 | 26.74 | 29.33 | 29.73 | 22.75 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | 0.0% | 0.0% | 1.7% | 12.7% | 5.6% | 2.9% |
| Payout Ratio | — | — | — | — | — | 0.3% | 2.2% | — | — | 86.8% | 58.3% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | 1.5% | 6.8% | 1.7% | — | — | 6.4% | 5.0% |
| FCF Yield | 100.0% | — | — | 36.5% | 10.6% | 2.3% | 16.3% | 36.4% | 13.1% | 0.5% | 7.3% |
| Buyback Yield | 65.2% | 4.7% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.4% | 3.3% |
| Total Shareholder Yield | 65.2% | 4.7% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 1.7% | 12.7% | 6.0% | 6.2% |
| Shares Outstanding | — | $77M | $77M | $76M | $76M | $75M | $64M | $61M | $60M | $60M | $61M |
Includes 30+ ratios · 30 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ACH stock.
Accendra Health, Inc.'s current P/E ratio is -0.0x. The historical average is 23.9x.
Accendra Health, Inc.'s current EV/EBITDA is 9.9x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 10.7x.
Accendra Health, Inc.'s return on equity (ROE) is -2111.6%. The historical average is 5.3%.
Based on historical data, Accendra Health, Inc. is trading at a P/E of -0.0x. Compare with industry peers and growth rates for a complete picture.
Accendra Health, Inc. has 46.7% gross margin and 8.0% operating margin.
Accendra Health, Inc.'s Debt/EBITDA ratio is 5.1x, indicating high leverage. A ratio above 4x may signal elevated financial risk.
Key Metrics
Top Statement Risk
Insolvency and liquidity distress
Metrics are mathematically derived from official filings.
Distressed Multiples Reflect Structural Uncertainty
According to recent market data, OMI trades at a P/S ratio of 0.06 and an EV/EBITDA of 1.70, which, based on reported figures, suggests the market is pricing the company as a distressed turnaround play rather than a stable, utility-like medical distributor.
The extremely low valuation multiples appear to reflect deep skepticism regarding the company's ability to return to consistent profitability following recent net losses. Investors should monitor whether these depressed levels represent a value opportunity or a rational adjustment to the company's deteriorating equity base and ongoing operational restructuring.
Operating Margins Mask Net Losses
As reported in financial statements, OMI's operating margin of 0.99% highlights the razor-thin nature of its distribution business, while the negative net margin of -39.85% indicates that non-operating costs and impairments are currently overwhelming the company's core earning power.
The divergence between thin operating margins and deep net losses suggests that the company's capital structure and historical acquisition-related costs are creating a significant drag on bottom-line performance. This pattern warrants further investigation into whether the current cost base is sustainable without further divestitures or significant operational efficiency gains.
Working Capital Volatility Impairs Liquidity
Based on the provided quarterly data, OMI's CCC has fluctuated wildly, reaching -162 days in 2025Q3, which, according to recent filings, suggests that the company's cash conversion cycle is highly sensitive to the timing of hospital payments and inventory management in a low-margin environment.
The extreme swings in DSO and DPO indicate that the company may be utilizing aggressive working capital management to bridge liquidity gaps. Such volatility suggests that OMI's operational efficiency is currently secondary to the urgent need to manage cash flow amidst persistent net losses.
Debt Service Capacity Remains Strained
As indicated by the reported figures, OMI's interest coverage ratio has frequently dipped below 1.0x, such as the 0.91x observed in 2025Q3, which suggests that the company's ability to service its debt obligations is increasingly precarious given the current level of operational distress.
The high debt-to-EBITDA levels, which reached 24.25x in 2025Q3, imply that the company's leverage is significantly elevated compared to historical norms and industry peers. This situation warrants close monitoring, as any further decline in operating performance could trigger covenant violations or necessitate dilutive capital raises.
Misapplication of P/E Multiples
The P/E ratio is frequently misapplied to OMI, as the company's recent history of net losses and significant non-cash impairments renders earnings-based valuation metrics largely meaningless for assessing the underlying health of the business model.
Investors should instead focus on EV/EBITDA or cash-flow-based metrics to better understand the company's operational viability, as the P/E ratio obscures the impact of one-time charges and interest burdens. Relying on P/E in this context may lead to a fundamental misunderstanding of the company's true cash-generating potential.